Olmesartan Medoxomil/Levamlodipine

The main purpose of the study is to evaluate the pharmacokinetic characteristics of Olmesartan Medoxomil-Levoamlodipine Tablets (each tablet contains 20 mg of Olmesartan Medoxomil and 2.5 mg of Levoamlodipine Besylate (calculated as C20H25ClN2O5)) taken simultaneously with Olmesartan Medoxomil Tablets (trade name: Aotan, 20 mg) and Amlodipine Besylate Tablets (trade name: Norvasc, 5 mg) in healthy subjects, and to evaluate the bioequivalence of the two in the fasting and postprandial state. Secondary purpose of the study is to evaluate the safety of Olmesartan Medoxomil-Levoamlodipine Tablets (each tablet contains 20 mg of Olmesartan Medoxomil and 2.5 mg of Levoamlodipine Besylate (calculated as C20H25ClN2O5)) taken simultaneously with Olmesartan Medoxomil Tablets (trade name: Aotan, 20 mg) and Amlodipine Besylate Tablets (trade name: Norvasc, 5 mg) in healthy subjects.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation Olmesartan Medoxomil Levoamlodipine Tablets (produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparations Olmesartan Medoxomil Tablets (trade name: Aotan, produced by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.) and Amlodipine Besylate Tablets (trade name: Norvasc, produced by Pfizer Pharmaceuticals Co., Ltd.) in healthy Chinese adult subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study is to evaluate the safety of the test preparation Olmesartan Medoxomil Levoamlodipine Tablets and the reference preparations Aotan and Norvasc in healthy Chinese adult subjects.